AbbVie

Los Angeles, California

OncologyADCPhase IIIListed · ABBV

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase II trial registered: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Feb 6, 2026
Solid Tumors · AVAILABLE · sponsor: AbbVie · Expanded Access to Telisotuzumab Adizutecan
ClinicalTrials.gov · NCT05982873 (opens the source filing in a new tab)
Trial
Study registered
Jan 27, 2026
Migraine · RECRUITING · sponsor: AbbVie · Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
ClinicalTrials.gov · NCT07310290 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 25, 2025
Small Cell Lung Cancer · RECRUITING · sponsor: AbbVie · A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov · NCT07155174 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 21, 2025
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant · RECRUITING · sponsor: AbbVie · A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
ClinicalTrials.gov · NCT06890338 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jul 23, 2025
Multiple Myeloma · RECRUITING · sponsor: AbbVie · A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ClinicalTrials.gov · NCT06953960 (opens the source filing in a new tab)
Trial
Study registered
Jun 4, 2025
Parkinson Disease · RECRUITING · sponsor: AbbVie · Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
ClinicalTrials.gov · NCT06965374 (opens the source filing in a new tab)
Trial
Study registered
Mar 28, 2025
Diffuse Large B-cell Lymphoma, Follicular Lymphoma · RECRUITING · sponsor: AbbVie · Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
ClinicalTrials.gov · NCT06830759 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 8, 2024
Metastatic Colorectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
ClinicalTrials.gov · NCT06614192 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 23, 2024
Major Depressive Disorder (MDD) · TERMINATED · sponsor: AbbVie · A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
ClinicalTrials.gov · NCT06618118 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 15, 2024
Bipolar I Disorder, Bipolar II Disorder · COMPLETED · sponsor: AbbVie · Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
ClinicalTrials.gov · NCT06605599 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 8, 2024
Metastatic Castration-Resistant Prostate Cancer · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov · NCT06318273 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 29, 2024
Healthy Volunteers · COMPLETED · sponsor: AbbVie · A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
ClinicalTrials.gov · NCT06148181 (opens the source filing in a new tab)
Trial
Study registered
Nov 30, 2023
Parkinson's Disease (PD) · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
ClinicalTrials.gov · NCT05916157 (opens the source filing in a new tab)
Trial
Study registered
Jun 25, 2023
Migraine · COMPLETED · sponsor: AbbVie · An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
ClinicalTrials.gov · NCT05827887 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 7, 2022
Perioral Lines · COMPLETED · sponsor: AbbVie · A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
ClinicalTrials.gov · NCT05454033 (opens the source filing in a new tab)
Trial
Study registered
Jan 6, 2022
Endometriosis, Uterine Fibrioids · TERMINATED · sponsor: AbbVie · A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
ClinicalTrials.gov · NCT04464187 (opens the source filing in a new tab)
Trial
Study registered
May 31, 2021
Psoriasis · COMPLETED · sponsor: AbbVie · Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
ClinicalTrials.gov · NCT04818385 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 11, 2020
Myelofibrosis (MF) · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
ClinicalTrials.gov · NCT04454658 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 8, 2019
Myeloproliferative Neoplasm · ACTIVE_NOT_RECRUITING · sponsor: AbbVie · A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
ClinicalTrials.gov · NCT04041050 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 12, 2017
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) · RECRUITING · sponsor: AbbVie · A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov · NCT02966756 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.96{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.96{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.78{"reasons":["name similarity 100%","shared principal investigator / founder","same city","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
new_entity links the trial record at 0.50{"reasons":["name similarity 100%"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
4w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
4w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
4w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
7w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
2mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
3mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
5mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
5mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Expanded Access to Telisotuzumab Adizutecan
5mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
6mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
9mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
10mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
Jan 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

Study registered

Study registered

PHASE2 registered

PHASE2 registered

PHASE1/PHASE2 registered

Study registered

Study registered

PHASE3 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

Study registered

Study registered

PHASE3 registered

Study registered

Study registered

PHASE1 registered

PHASE1 registered

PHASE2 registered